<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Utah-based AI biotech company Recursion Pharmaceuticals and Bayer have expanded the existing research collaboration (initially entered in September 2020) for cancer treatments.
      </p>
    </li>
    <li>
      <p>
        The collaboration will leverage Recursion&rsquo;s AI technology and Bayer's small-molecule compound library to identify new treatment options for cancer. The partnership could improve the speed and efficiency of identifying potential therapies, with the companies planning to initiate up to seven oncology programs. Recursion will receive up to USD 1.5 billion in potential payments and royalties under the terms of the agreement.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://ir.recursion.com/news-releases/news-release-details/bayer-and-recursion-focus-research-collaboration-oncology">
      Press release - Recursion
    </a>
  </p>
  <p>
    <a href="https://www.bayer.com/media/en-us/bayer-and-recursion-focus-research-collaboration-on-oncology/">
      Press release - Bayer&nbsp;
    </a>
  </p>
  <p>
    <a href="https://pharmaphorum.com/news/bayer-pledges-15bn-recursion-oncology-alliance">
      Pharmaphorum
    </a>
  </p>
  <p>
  </p>
</div>


Longevity Tech

DISRUPTOR_PRESENT

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
  <ul>
    <li>
      <p>Utah-based AI biotech company Recursion Pharmaceuticals and Bayer have expanded their research collaboration for cancer treatments. The collaboration will use Recursion's AI technology and Bayer's compound library to identify new treatment options for cancer. They plan to start up to seven oncology programs, aiming to improve the speed and efficiency of finding potential therapies. Recursion could receive up to USD 1.5 billion in payments and royalties as part of the agreement.</p>
    </li>
  </ul>
</div>

Recursion and Bayer expand partnership for cancer drug discovery

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 <ul>
  <li><p>Utah-based AI biotech company Recursion Pharmaceuticals and Bayer have expanded the existing research collaboration (initially entered in September 2020) for cancer treatments.</p></li>
  <li><p>The collaboration will leverage Recursion’s AI technology and Bayer's small-molecule compound library to identify new treatment options for cancer. The partnership could improve the speed and efficiency of identifying potential therapies, with the companies planning to initiate up to seven oncology programs. Recursion will receive up to USD 1.5 billion in potential payments and royalties under the terms of the agreement.</p></li>
 </ul> 
</div>

All Updates

Recursion and Bayer expand partnership for cancer drug discovery

Recursion and Bayer expand partnership for cancer drug discovery

Recursion misses EPS estimate by thin margin in Q2 2023

Recursion secures USD 50 million PIPE investment and partnership from NVIDIA

Recursion reports 128.3% YoY revenue growth in Q1 2023

Recursion reports 71% QoQ revenue growth in Q3 2022

Recursion Pharmaceuticals raises USD 150 million in private placement

Recursion misses EPS analyst estimate despite 45% QoQ revenue growth

Recursion secures AI deal from Roche worth up to USD 12 billion

Recursion Pharmaceuticals collaborates with Mila for drug discovery